EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/1516463
SPRING 2024 | EYEWORLD | 97
G
References (continued)
8. Lam LA, et al. Intravitreal injec-
tion therapy: current techniques
and supplemental services. J
Vitreoretin Dis. 2021;5:438–447.
9. Liu KC, et al. Recurrent tube
erosions with anti-vascular en-
dothelial growth factor therapy
in patients with age-related mac-
ular degeneration. Ophthalmol
Glaucoma. 2020;3:295–300.
10. Pirinen I, et al. Glaucoma
progression in patients receiving
intravitreal anti-VEGF treatment
for neovascular age-related
macular degeneration. Acta
Ophthalmol. 2023;101:261–265.
11. Du J, et al. Effects of intra-
vitreal anti-VEGF therapy on
glaucoma-like progression in
susceptible eyes. J Glaucoma.
2019;28:1035–1040.
12. Hoang QV, et al. Effect on
intraocular pressure in patients
receiving unilateral intravitreal
anti-vascular endothelial growth
factor injections. Ophthalmolo-
gy. 2012;119:321–326.
13. Wen JC, et al. Intravitreal
anti-VEGF injections reduce
aqueous outflow facility in
patients with neovascular
age-related macular degenera-
tion. Invest Ophthalmol Vis Sci.
2017;58:1893–1898.
14. Bilgic A, et al. Sustained
intraocular pressure rise after
the treat and extend regimen
at 3 years: aflibercept versus
ranibizumab. J Ophthalmol.
2020;2020:7462098.
15. Cui QN, et al. Repeated intra-
vitreal injections of antivascular
endothelial growth factors and
risk of intraocular pressure medi-
cation use. Graefe's Arch Clin Exp
Ophthalmol. 2019;257:1931–1939.
16. Matlach J, et al. Investigation
of intraocular pressure fluctua-
tion as a risk factor of glaucoma
progression. Clin Ophthalmol.
2018;13:9–16.
She noted that other studies suggest that
higher postoperative IVIs in incisional glaucoma
surgery may improve outcomes.
"A study by Chang et al. found that >7 IVIs
after traditional glaucoma surgery was associat-
ed with improved success (IOP reduction ≥20%
with 5